Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells

Phase II study of sorafenib in patients with relapsed or refractory lymphoma

(2012) Anna Guidetti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Sorafenib Inhibits Hypoxia-Inducible Factor-1  Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma

(2012) L.-p. Liu et al.   CLINICAL CANCER RESEARCH

Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

(2011) Vijay Ramakrishnan et al.   AMERICAN JOURNAL OF HEMATOLOGY

BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines

(2011) Katrin Ullrich et al.   BRITISH JOURNAL OF HAEMATOLOGY

Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation

(2011) Bjoern Chapuy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia

(2011) Shuiying Hu et al.   JNCI-Journal of the National Cancer Institute

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1

(2011) S Huber et al.   LEUKEMIA

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

(2011) A. Bottos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature

(2010) C. Lavazza et al.   BLOOD

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis

(2010) Tri K. Nguyen et al.   LEUKEMIA RESEARCH

A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments

(2009) Marco Righi et al.   LABORATORY INVESTIGATION

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

(2008) Vandana Gupta-Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE